Founded in 2020, Virusight Diagnostic is a JV between Newsight Imaging ltd and Sheba Medical Center – one of the top 10 hospitals in the world. Virusight is an AI company, that uses unique spectral acquisition and analysis technology for pathogens detection. The company is developing revolutionary COVID-19 rapid tests, based on Newsight Imaging’s spectral device, that successfully identifies the virus in just one second! With a high correlation to PCR, this technology is a real game-changer for immediate and affordable mass screening.
Rotem Sorek
[email protected]
https://virusight.co.il/
Our Representatives
Company Solutions
Real Time Pathogens Detection
Virusight is an AI software company that uses Newsight Imaging’s unique innovative spectrometer device - the SpectraLIT™, to detect pathogens in human samples (both oral rinse and Nasopharyngeal swab samples). The device can test a swab's UTM liquid, and potentially mouthwash, using an absorbance spectrographic method.
Virusight’s technology uses AI modules to classify spectral signatures of different pathogens found in body fluids, obtained by the SpectraLIT™. The solution detects the spectral signature of the reaction of the subject to the virus and using Virusight’s AI and machine learning technology, we can immediately differentiate between sick and healthy.
After proving the technology on tropical viruses in a pre-clinical trial at Sheba Medical Center, the company has started developing a COVID-19 module, to enable fast screening of the virus to release the blocked industries thus lifting the burden on world’s economy. Accurate rapid testing at any point of care will assist to prevent virus spread and allow treating patients to their relevant conditions on time (preventing crucial misdiagnosis due to COVID).
Regulations and Worldwide Pilots
The solution is currently in clinical trials with over 35 pilots in leading hospitals around the world. Results of the trials are showing high correlation to PCR diagnosis and will soon be submitted for regulatory CE and EUA (FDA) approvals.
Variants and Other Pathogens
Using AI, Virusight’s solution improves the accuracy of the results overtime, and can easily be adapted to mutations using a simple software update. The solution has been proven to identify other pathogens such as Dengue fever and Chikungunya in a pre-clinical trial taken place in Sheba Hospital. Looking forward to a post-Coronavirus era, Virusight aims to become a major player in the field of immediate pathogens detection, at any point of care.
Looking For
We are looking for Healthcare players, medical devices, Pharma companies and other strategic partners with whom we could collaborate to open and expand new market opportunities